PureTech starts phase 2 trial of LYT-100 in long COVID-19 respiratory complications and related sequelae

▴ PureTech starts phase 2 trial of LYT-100 in long COVID-19 respiratory complications and related sequelae
PureTech’s global, randomized, double-blind, placebo-controlled Phase 2 trial is designed to evaluate the efficacy, safety and tolerability of LYT-100 in adults with post-acute COVID-19 respiratory complications

PureTech Health plc, a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, recently announced the initiation of its global, Phase 2 trial of LYT-100 (deupirfenidone) in Long COVID respiratory complications and related sequelae. LYT-100 is PureTech’s wholly-owned product candidate that is being advanced for the potential treatment of conditions involving inflammation and fibrosis and disorders of lymphatic flow. The initiation follows the completion of a Phase 1 multiple ascending dose and food effect study for LYT-100, which demonstrated favorable proof-of-concept for LYT-100’s tolerability and pharmacokinetic (PK) profile.

Fibrosis and inflammation are common mechanisms across several lung diseases, and there is increasing data that respiratory complications of SARS-CoV-2 (COVID-19), including shortness of breath, begin during the acute phase of illness and may persist as lung fibrosis develops. Similar respiratory complications caused by Severe Acute Respiratory Syndrome (SARS) lasted for years in many survivors. According to a research letter published in the Journal of the American Medical Association (JAMA), more than 40 per cent of COVID-19 survivors assessed in an Italian study still reported shortness of breath an average of 60 days following symptom onset. These data suggest that a significant percentage of COVID-19 survivors may be at risk for respiratory complications and other sequelae, which is a condition that is now colloquially referred to as “Long COVID.”

“COVID-19 is a global public health crisis with severe and long-lasting effects. Patients around the world have reported persistent suffering, including serious respiratory complications that can last for months after the acute infection resolves, and – even with vaccines – there is great a need for treatment options for Long COVID,” said Toby Maher, M.D., Ph.D., professor of clinical medicine and director of interstitial lung disease at Keck School of Medicine of the University of Southern California and the principal investigator on PureTech’s Long COVID Phase 2 trial. “The anti-fibrotic and anti-inflammatory properties of LYT-100 hold potential for treating a range of respiratory conditions, including the long-lasting health burden associated with post-acute COVID-19. I am encouraged by the data generated with LYT-100 to date, and I am excited to be involved in this trial addressing a critically important public health need in the current COVID-19 pandemic.”

LYT-100 is a deuterated, oral small molecule designed to overcome the challenges associated with pirfenidone, an approved and marketed anti-inflammatory and anti-fibrotic drug. Pirfenidone is currently approved for the treatment of idiopathic pulmonary fibrosis (IPF), but it is associated with significant tolerability issues and dose-limiting toxicities. LYT-100, a new chemical entity, retains the pharmacology of pirfenidone but has a differentiated PK profile, which is designed to enable improved tolerability, less frequent dosing and potentially increased efficacy.

PureTech’s global, randomized, double-blind, placebo-controlled Phase 2 trial is designed to evaluate the efficacy, safety and tolerability of LYT-100 in adults with post-acute COVID-19 respiratory complications. The primary endpoint of the trial will be the six-minute walk test distance. Secondary endpoints, including pharmacokinetics, inflammatory biomarkers, imaging and patient-reported outcomes including dyspnea and the 36-Item Short Form Health Survey, will also be evaluated. The study has initiated in both the United States and Europe, and results are expected in the second half of 2021.

Tags : #PureTechHealth #LatestNewsonPureTechHealth5thDec #LatestPharmaNews5thDec #LatestNewsonCOVIDTreatment5thDec #LongCovid #JournaloftheAmericanMedicalAssociation

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

A New Dawn for Eye Health in Obesity: How Bariatric Surgery Repairs Early Eye DamageDecember 14, 2024
Healing Invisible Wounds: How Indian Government’s Bold Initiatives Are Tackling the Mental Health CrisisDecember 14, 2024
The 8-Hour Miracle: Here’s How Doctors Rewrote a Young Girl’s FateDecember 14, 2024
University of Manchester invites applications for MSc Climate Change: Science, Society and Solutions December 13, 2024
Pollution vs. Population: Can India Survive Its Toxic Air?December 13, 2024
New Milestone: First Cryopreserved Stem Cell Donation Helps Blood Cancer Patient December 13, 2024
Everest Medicines Announces the First Prescription of VELSIPITY(R) Issued in MacauDecember 13, 2024
Plastic Pollution Goes Personal: Microplastics Found in Human BloodDecember 12, 2024
The Fat-Fuelled Weapon Against Cancer: How the Keto Lifestyle is Redefining Cancer TherapyDecember 12, 2024
Gene Therapy in India: How Indian Scientists Redefined Hemophilia TreatmentDecember 12, 2024
Empowering India’s Workforce: FinX Raises $6M from Elevar Equity to revolutionise employability in the BFSI IndustryDecember 12, 2024
India’s Win Over Malaria: A Global Health Victory in ProgressDecember 11, 2024
TB-Free India by 2025: Bold Vision or Achievable Reality?December 11, 2024
Aakash Healthcare Supports the 14th Special Athletic Meet for Children with Special NeedsDecember 11, 2024
The University of Manchester invites applications for an MSc in International Disaster ManagementDecember 10, 2024
Preventing Mother-to-Child HIV Transmission: Strategies and ImportanceDecember 10, 2024
USIBC Signs MOU with Government of Telangana, Hosts AI and GCC Industry RoundtableDecember 10, 2024
CarDekho Group’s New Auto Segment’s Shift in Fuel Preferences Report: Electric Vehicles (EVs) Lead the Chart with 26% YoY Traffic Increase December 10, 2024
India’s leading eCommerce enablement platform Shiprocket appoints industry veteran Vivek Sharma as VP of International ShippingDecember 10, 2024
Failure to find all TB cases defeats us in #endTB effortsDecember 10, 2024